Atelocollagen-mediated systemic DDS for nucleic acid medicines.

Abstract

The goal of our research is to provide a practical platform for drug delivery in oligonucleotide therapy. We report here the efficacy of an atelocollagen-mediated oligonucleotide delivery system applied to systemic siRNA and antisense oligonucleotide treatments in animal disease models. Atelocollagen and oligonucleotides formed a complex of nanosized particles, which was highly stable against nucleases. The complex allowed oligonucleotides to be delivered efficiently into several organs and tissues via intravenous administration. In a tumor metastasis model, the complex successfully delivered siRNA to metastasized tumors in bone tissue and inhibited their growth. We also demonstrated that a single intravenous treatment of the antisense oligodeoxynucleotide complex suppressed ear dermatitis in a contact hypersensitivity model. These results indicate the strong potential of the atelocollagen-mediated drug delivery system for practical therapeutic technology.

• Authors: Koji Hanai, Fumitaka Takeshita, Kimi Honma, Shunji Nagahara, Miho Maeda, Yoshiko Minakuchi, Akihiko Sano, Takahiro Ochiya
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1082 Pg. 9-17 (Oct 2006) ISSN: 0077-8923 [Print] United States
• PMID: 17145919 (Publication Type: Journal Article)

Chemical References

• Drug Carriers
• Oligonucleotides
• RNA, Small Interfering
• atelocollagen
• Collagen

Topics

• Animals
• Bone Neoplasms (secondary)
• Collagen (therapeutic use)
• Dermatitis (therapy)
• Disease Models, Animal
• Drug Carriers (chemistry)
• Genetic Therapy (methods)
• Humans
• Hypersensitivity (drug therapy)
• Mice
• Mice, Nude
• Nanoparticles
• Neoplasm Metastasis (drug therapy)
• Oligonucleotides (administration & dosage)
• RNA, Small Interfering (administration & dosage)
• Tissue Distribution